CHICAGO — Bristol-Myers Squibb Co. has high hopes for its strategy of combining the PD-1 inhibitor Opdivo and the CTLA-4 inhibitor Yervoy in a range of indications, buoyed by updated Phase Ib data from the CheckMate 012 study in first-line non-small cell lung cancer.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?